Inactivation of the transcription factor p53, through either direct mutation or aberrations in
one of its many regulatory pathways, is a hallmark of virtually every tumor. In recent years …

The standard classification used to define the various cancer genes confines tumor protein
p53 (TP53) to the role of a tumor suppressor gene. However, it is now an indisputable fact …

Tumor suppressor p53 is inactivated by thousands of heterogeneous mutations in cancer,
but their individual druggability remains largely elusive. Here, we evaluated 800 common …

The tumor suppressor protein p53 induces or represses the expression of a variety of target
genes involved in cell cycle control, senescence, and apoptosis in response to oncogenic or …

TP53 is the most frequently mutated tumor suppressor gene in human cancer, with nearly
50% of all tumors exhibiting a loss-of-function mutation. To further elucidate the genetic …

The tumor suppressor protein p53 is inactivated by mutation in about half of all human
cancers. Most mutations are located in the DNA-binding domain of the protein. It is …

OVER THE PAST DECADE, gene therapy has been increasingly applied in clinical trials.
According to data published by the Journal of Gene Medicine (http://www. wiley. co …

The DNA-binding domain of the tumor suppressor p53 is inactivated by mutation in≈ 50% of
human cancers. We have solved high-resolution crystal structures of several oncogenic …

TP53 mutations are common in lung cancers of smokers, with high prevalence of G: C-to-T:
A transversions generally interpreted as mutagen fingerprints of tobacco smoke. In this …

The p53 tumor suppressor gene is the most frequently mutated gene in cancer. Most p53
mutations are missense point mutations that cluster in the DNA-binding core domain. This …